市場調查報告書
商品編碼
1308576
到 2030 年超聲心動圖(心臟超聲設備)市場預測:按類型、設備展示、技術、最終用戶和地區進行的全球分析Echocardiography Market Forecasts to 2030 - Global Analysis By Type, Device Display (CCD Colour Display and Black & White Display), Technology, End User and By Geography |
根據Stratistics MRC 的數據,2023 年全球超聲心動圖(心臟超聲機)市場規模將達到19 億美元,預測期內復合年增長率為9.5%,到2030 年將達到35 %。預計將達到1億美元。
超聲心動圖通常稱為迴聲或心臟超聲機,使用聲波創建心臟圖像以查找心血管疾病。 該工具可用於查找血塊、檢查心室和瓣膜。 經胸超聲心動圖、經食管超聲心動圖和負荷超聲心動圖是三種不同的心臟超聲機器,可用於各種診斷程序。 由於其非侵入性,經胸超聲心動圖是識別心臟問題最常用的診斷程序。
根據英國心臟基金會 2022 年發布的數據,英國約有 15 億人被診斷患有房顫。
心髒病患病率的上升增加了對微創心臟手術的需求。 此外,結合ICE和其他成像方式的集成系統的開發以及超聲心動圖系統的技術發展(例如圖像質量的提高)預計將進一步促進市場擴張。 由於疼痛更輕、住院時間更短、恢復更快,微創心臟手術的需求也很高。 這些手術通常使用超聲心動圖來引導導管和其他裝置插入心臟。
使用超聲心動圖需要專門的培訓和專業知識。 缺乏能夠操作這些系統的熟練專業人員可能會限制部署。 此外,還有其他成像技術,例如經食管超聲心動圖(TEE)和磁共振成像(MRI),它們可能會與超聲心動圖爭奪市場份額。
在超聲心動圖市場,人們對便攜式超聲檢查的興趣與日俱增。 診斷性放射性核素心動圖與超聲心動圖面臨著重大的競爭挑戰。 然而,脈衝多普勒的改進使得將可靠的探針植入食道並提高心臟成像的分辨率成為可能。 超聲心動圖行業的公司在聲學量化方法的研發 (R&D) 上投入了大量資金,這些方法有助於識別和跟蹤心肌內緣和血池相交的線,使超聲心動圖成為醫生的首選。到
便攜式心臟超聲機有一些局限性。 儘管尺寸很小,但屏幕很小並且會影響診斷。 由於超聲頻率低,分辨率低,圖像優化不佳。 此外,有時僅提供 2D 圖像。 因此,這些設備體積龐大且價格昂貴,因此它們可能在未來幾年內不會流行。
在新冠肺炎 (COVID-19) 疫情期間,市場增長放緩。 下降的原因是前往診所和醫院診斷和治療心血管疾病的患者減少以及非緊急手術的推遲。 2020年全球市場同比下降8.3%。 在此期間,非 COVID-19 相關的診斷程序被認為是低優先級,導致心血管疾病檢測顯著減少。
心內超聲心動圖部分是一種稱為心內超聲心動圖(ICE) 的醫學成像程序,它使用插入心臟的小型超聲探頭來生成心室、瓣膜和靜脈的圖像。因此,預計會有良好的增長。 心髒病發病率的增加、對微創心臟手術的需求以及改進的 ICE 系統技術帶來了更高的準確性和利用率,推動了這一市場的發展。
預計 3D 和 4D 細分市場在預測期內的複合年增長率最高。 該技術卓越的圖像質量、逼真的解剖圖像、體積測量能力以及識別間隔異常的能力促進了這一領域的增長。
由於新產品和創新產品的廣泛接受、對各種可用醫療程序的了解以及支持醫療程序的強大基礎設施投資,北美將在預測期內繼續增長。預計將佔據最大的市場份額在 推動該地區市場的其他重要因素包括政府對醫療基礎設施和超聲心動圖研究與開發的有利支持。
預計亞太地區在預測期內的複合年增長率最高。 這是由於印度和中國有大量人口受到心血管疾病的影響,以及亞太地區存在未開發的潛力和人們對醫療狀況的認識不斷提高,從而促進了市場的增長。 由於吸煙、超重和血糖水平升高等生活方式因素,南亞、印度、中國和澳大利亞患心血管疾病的風險很高。
2022年9月,三星電子有限公司宣布推出V7超聲系統。 該系統具有 AutoIMT 工具,用於分析患者潛在的心血管疾病風險。
2022 年 3 月,Koninklijke Philips N.V. 在美國心髒病學會年度科學會議暨博覽會 (ACC 2022) 上宣布推出超聲工作區。
2022 年 2 月,Koninklijke Philips N.V. 在其 Lumify 手持式超聲系統中添加了脈衝多普勒技術。 此次更新旨在擴展設備的血流動力學評估和測量功能。
According to Stratistics MRC, the Global Echocardiography Market is accounted for $1.9 billion in 2023 and is expected to reach $3.5 billion by 2030 growing at a CAGR of 9.5% during the forecast period. Echocardiography, commonly known as an echo or cardiac ultrasound, creates images of the heart using sound waves in order to look for any cardiovascular illness. With the use of this tool, blood clots may be found and the chambers and valves of the heart can be studied. Transthoracic, transesophageal, and stress cardiac ultrasonography are three different cardiac ultrasound examinations that are utilised for various diagnostic procedures. Due to its non-invasive nature, transthoracic cardiac ultrasonography is the most often utilised diagnostic procedure for identifying heart problems.
According to the British Heart Foundation data published in 2022, around 1.5 billion people in the U.K. have been diagnosed with atrial fibrillation.
The rising incidence of heart disease and the rising demand for less invasive cardiac operations. Additionally, the development of integrated systems that combine ICE with other imaging modalities and technological developments in echocardiography systems, such as enhanced picture quality, are anticipated to further propel market expansion. Additionally there is an increasing demand for minimally invasive cardiac operations since they are less painful, require fewer hospital stays, and have quicker recovery times. During these surgeries, echocardiography is frequently utilised as a guide for inserting catheters and other devices into the heart.
The use of echocardiography requires specialized training and expertise. The shortage of skilled professionals who can operate these systems may limit its adoption. Moreover there are alternative imaging techniques, such as transesophageal echocardiography (TEE) and magnetic resonance imaging (MRI), which may compete with echocardiography for market share.
The market for echocardiography is seeing an increase in interest in the idea of portable ultrasound. Nuclear cardiology for diagnostic purposes faces a significant competitive challenge from echocardiography. However, improvements in pulse doppler are making it possible to implant trustworthy probes into the oesophagus to increase the resolution of cardiac imaging. Companies in the echocardiography industry are investing more in research and development (R&D) for acoustic quantification methods that aid in identifying and keeping track of the line where the inner margin of the myocardium and blood pool meets is encouraging the doctors to much prefer echocardiography.
Portable cardiac ultrasonography equipment has several restrictions. Despite being smaller in size, they have a smaller screen, which may affect the diagnosis. With fewer ultrasonic frequencies, the resolution is poorer, and the image optimisation is subpar. Additionally, they may only use 2D pictures. As a result, the bulk and expensive price of these gadgets may prevent widespread use in the years to come.
During COVID-19, the market experienced a decline in its growth. Fewer patients visiting the clinics and hospitals for cardiovascular disease diagnosis and treatment and the postponement of non-emergency procedures were responsible for the decline. The global market experienced a decline of 8.3% in 2020 as compared to the past year. During this period, non-COVID-19-related diagnostic procedures were considered low-priority, which caused a significant decrease in the testing volume of cardiovascular disorders.
The Intracardiac Echocardiography segment is estimated to have a lucrative growth, due to the use of a tiny ultrasonic probe that is put within the heart, a medical imaging procedure known as intracardiac echocardiography (ICE) can produce pictures of the heart's chambers, valves, and blood veins. The market is fuelled by reasons such the increased incidence of heart illness, the need for less invasive cardiac operations, and improvements in ICE system technology that increase its accuracy and use.
The 3D & 4D (Three-Dimensional Echocardiography & 4DEchocardiography) segment is anticipated to witness the highest CAGR growth during the forecast period, due to The characteristics of this technology, including as good picture quality, realistic anatomical images, the capacity to offer volume measurement, and the ability to see septal abnormalities, have contributed to the segment's rise.
North America is projected to hold the largest market share during the forecast period owing to widespread acceptance of new and innovative goods, great knowledge of the range of medical treatments available, and major infrastructure investment supporting medical treatments. Other significant drivers propelling the market in the area include favourable government assistance for healthcare infrastructure and research and development of echocardiography.
Asia Pacific is projected to have the highest CAGR over the forecast period, owing to the vast population suffering from cardiovascular illnesses in India and China, combined with the presence of unexplored potential and increased awareness of medical conditions in Asia Pacific, all contribute to the market's growth. Due to lifestyle factors including smoking, excessive weight, and elevated blood sugar levels, the risk of cardiovascular disease is higher in South Asia, India, China, and Australia.
Some of the key players profiled in the Echocardiography Market include Siemens Healthcare GmbH, Conavi Medical, Boston Scientific Corporation, Abbott Laboratories, Koninklijke Philips NV, Goodman USA, Inc, Shifamed LLC (NuVera Medical), Johnson & Johnson Services Inc., Stereotaxis Inc., GE Healthcare, B. Braun Melsungen AG, FUJIFILM Holdings Corporation, SAMSUNG ELECTRONICS Co., Ltd, ESAOTE SPA, Meditronic, Terumo Corporation and St. Jude Medical
In September 2022, Samsung Electronics Co., Ltd. announced the launch of V7 ultrasound system. The system possesses AutoIMT tool for analyzing a patient's potential risk for cardiovascular disease.
In March 2022, Koninklijke Philips N.V. announced the launch of Ultrasound Workspace at the American College of Cardiology's Annual Scientific Session & Expo (ACC 2022).
In February 2022, Koninklijke Philips N.V. added Pulse Wave Doppler technology to Lumify, a handheld ultrasound device. The update aims to expand the hemodynamic assessment and measurement capabilities of the system.